Last reviewed · How we verify
Repository Corticotropin Injection
Repository Corticotropin Injection, marketed by Mallinckrodt, holds a unique position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and lack of direct generic competition until the patent expiry. However, the primary risk is the potential for increased competition post-2028, which could impact revenue and market share.
At a glance
| Generic name | Repository Corticotropin Injection |
|---|---|
| Also known as | H.P. Acthar Gel (repository corticotropin injection), Acthar, ACTH Gel, ACTH, H.P. Acthar Gel |
| Sponsor | Mallinckrodt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Use of Acthar in Rheumatoid Arthritis (RA) Related Flares (PHASE4)
- Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses (PHASE4)
- The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis (PHASE3)
- Ocular Sarcoidosis Open Label Trial of ACTHAR Gel (NA)
- Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) (EARLY_PHASE1)
- Acthar Gel in Participants With Pulmonary Sarcoidosis (PHASE4)
- Adrenocorticotropic Hormone in Membranous Nephropathy (PHASE4)
- Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Repository Corticotropin Injection CI brief — competitive landscape report
- Repository Corticotropin Injection updates RSS · CI watch RSS
- Mallinckrodt portfolio CI